Translational Strategy Director, Oncology & Biomarkers

Merck & Co.; Basking Ridge (NJ); On-site; USD 234,000 - 391,000; Full time

Job summary

Daiichi Sankyo, Inc. seeks a senior translational medicine leader to define and oversee strategy across multiple indications. The role drives clinical development questions, aligns with global teams, and works with laboratories in Japan to steer translational activities.

Responsibilities include constructing translational plans, biomarker analyses, regulatory support, and collaboration with external experts to advance program milestones and patient selection strategies.

Qualifications

• MD/PhD/PharmD or equivalent with strong oncology translational background.
• Deep knowledge of biomarker technologies (NGS, immunoassays, proteomics, IHC) and assay validation.
• Exceptional communication skills to engage HA and KEEs on complex translational science.

Responsibilities

• Develop and oversee a translational plan for the program across all indications.
• Define key scientific questions and steps to answer them.
• Develop a companion diagnostic plan with the Companion Diagnostics group for all indications.
• Lead external collaborations and identify key experts; monitor progress of external research programs.
• Construct translational plan documents and biomarker analysis plans; assist in clinical development plans and regulatory submissions.
• Support commercial strategy including patient selection considerations.

Skills

Leadership

Biomarker technologies

Communication

Education

Master’s degree

PharmD/PhD/MD or equivalent

TA oncology training

Job description

Daiichi Sankyo, Inc. seeks a senior translational medicine leader to define and oversee strategy across multiple indications. The role drives clinical development questions, aligns with global teams, and works with laboratories in Japan to steer translational activities.

Responsibilities include constructing translational plans, biomarker analyses, regulatory support, and collaboration with external experts to advance program milestones and patient selection strategies.